Questionnaires to Assess Sexual Function
Linda Cardozo, Staskin David in Textbook of Female Urology and Urogynecology - Two-Volume Set, 2017
A new treAtment And probAbly hAs most utility in diAgnosis, Although even in diAgnosis there will be issues with concordAnce And reliAbility between cliniciAns due to the complex diAgnostic criteriA for FsD. utiAn et Al. [29] successfully developed A structured diAgnostic method for diAgnosing FsD, And DerogAtis et Al. [30] hAve recently developed A stAndArdized cliniciAn Assessment for diAgnosing hypoActive sexuAl desire disorder–women's sexuAl interest diAgnostic interview. In evAluAting the outcome of treAtments for both mAle sexuAl function And FsD, smAll lAb-bAsed studies hAve generAlly relied on An initiAl cliniciAn diAgnosis of sexuAl dysfunction, followed by An objective Assessment. LArger, rAndomized controlled triAls hAve used similAr cliniciAn diAgnosis of dysfunction but with subjective meAsures of outcome due to eAse of use.
Genitals
Lisa Jean Moore, Monica J. Casper in The Body, 2014
Like Fishman, journalist Ray Moynihan (2003) has suggested that researchers directly linked to pharmaceutical companies created the term “female sexual dysfunction” based on limited research as a means of constructing new markets for diagnosis and treatment of emerging “disorders.” Related terms include, for example, “female sexual arousal disorder” and “hypoactive sexual desire disorder.” This process is known as disease mongering, or the creation of pathological descriptions of normal bodily functioning for pharmaceutical profit (Payer 1992), which is related to biomedicalization (Clarke et al. 2009).
Physical Treatments for Sexual Problems
Philipa A Brough, Margaret Denman in Introduction to Psychosexual Medicine, 2019
Flibanserin is a centrally-acting agent licenced in the United States 2 years ago for the treatment of female sexual interest/arousal disorder (FSIAD) in pre-menopausal women. More recent studies have also shown some evidence for efficacy in treating hypoactive sexual desire disorder in post-menopausal women (16). However, studies into this and other newer agents such as bremelanotide are sponsored by the pharmaceutical industry, and there has been controversy in the United States about the awarding of the US Food and Drug Administration licence.
A Qualitative Study of Women’s Experiences with Cognitive-Behavioral and Mindfulness-Based Online Interventions for Low Sexual Desire
Published in The Journal of Sex Research, 2022
Milena Meyers, Jürgen Margraf, Julia Velten
Low desire is one of the most common sexual problems among women (Briken et al., 2020; Mitchell et al., 2013). A lack of sexual desire that is characterized by reduced or absent spontaneous desire (sexual thoughts or fantasies), reduced or absent responsive desire to erotic cues and stimulation, or an inability to sustain desire once sexual activity is initiated, which is present for at least several months, and is associated with clinically significant distress, can be diagnosed as hypoactive sexual desire dysfunction (International Classification of Diseases, ICD-11, HSDD, formerly hypoactive sexual desire disorder; World Health Organization [WHO], 2018). As women’s sexual health is closely related to their overall health, partnership satisfaction (Mitchell et al., 2013), as well as mental health (Laurent & Simons, 2009), developing and providing effective treatments for low sexual desire is expected to be beneficial to women’s general well-being (Biddle et al., 2009; Davison et al., 2009).
Mental disorder and social deviance
Published in International Review of Psychiatry, 2021
Awais Aftab, Mohammed Abouelleil Rashed
The limitation for such an account is that there will be instances where it will not be clear whether distress is a result of internalised social disapproval in the sense envisioned by Rashed and Bingham. Consider the case of hypoactive sexual desire disorder. How much of distress associated with low sexual desire is a direct result of the low sexual desire, and how much of it is due to our contemporary social norms that place a high emphasis on the need for an active sexual life (Aftab et al., 2017)? There is reason to suspect that it is a mixture of both: even in communities permissive of asexuality, a loss of sexual desire may nonetheless be distressing to the individual. Yet, at the same time, many who experience distress at their loss of sexual desire in contemporary Western societies may not be distressed if social attitudes were different.
A higher quality of life by the Cervantes Short-Form Scale is related to a better sexual desire in postmenopausal women
Published in Gynecological Endocrinology, 2021
Maria Fasero, Ana Rosa Jurado-López, Carlos San Martín-Blanco, David Varillas-Delgado, Pluvio J. Coronado
In this study, we found a significant correlation between Cervantes-SF and B-PFSF scores, where the higher Cervantes-SF scores (worsening HR-QoL) were related to lower B-PFSF scores (worsening sexual desire). We found that being a current smoker (better sexual desire) and to use vaginal hormonal treatment (worse sexual desire) were independent factors related to score on B-PFSF. These findings agree with other studies that relate hypoactive sexual desire disorder to HR-QoL but concluding that improvement in sexual desire is not related to currently approved treatments [24,25]. According to some authors the hypoactive sexual desire disorder could be treated with appropriate assessments, sex therapy and hormonal therapy that includes off-label use of testosterone, supported by data but not FDA approved [26]. This could explain findings in our study in which the perception of improvement in women with systemic or vaginal hormonal treatment is low. Our findings disagree with authors that consider the vaginal hormonal treatment as the best treatment to relieve vaginal symptoms and improved the sexual profile in menopausal women [3,5] and with other study that have also found the use of vaginal hormonal treatment is related to an improvement of the sexual profile by improving vulvovaginal atrophy [4].
Related Knowledge Centers
- Female Sexual Arousal Disorder
- Sexual Dysfunction
- Testosterone
- Menopause
- Serotonin
- Prolactin
- Sexual Stimulation
- Fear of Intimacy
- Relational Disorder
- Sexual ADDiction